Caxton Corp Mei Pharma, Inc. Transaction History

Caxton Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$2.73 - $4.5 $136,500 - $225,000	-50,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.6 - $3.32 $326,456 - $416,859	-125,560 Reduced 71.52%	50,000 $132,000
Q3 2020 Nov 16, 2020	SELL	$2.46 - $4.27 $295,200 - $512,399	-120,000 Reduced 40.6%	175,560 $548,000
Q2 2020 Aug 14, 2020	SELL	$1.45 - $4.3 $855,500 - $2.54 Million	-590,000 Reduced 66.62%	295,560 $1.22 Million
Q1 2020 May 15, 2020	BUY	$0.75 - $2.55 $30,000 - $102,000	40,000 Added 4.73%	885,560 $1.43 Million

Q3 2019 Nov 14, 2019	SELL	$1.48 - $2.52 $1.86 Million - $3.17 Million	-1,255,973 Reduced 59.76%	845,560 $1.42 Million
Q2 2019 Aug 14, 2019	SELL	$2.45 - $3.32 $3.33 Million - $4.51 Million	-1,357,591 Reduced 39.25%	2,101,533 $5.25 Million
Q4 2018 Feb 14, 2019	SELL	$1.92 - $4.1 $421,393 - $899,851	-219,476 Reduced 5.97%	3,459,124 $9.13 Million
Q3 2018 Nov 14, 2018	SELL	$3.39 - $4.61 $2.45 Million - $3.33 Million	-721,839 Reduced 16.4%	3,678,600 $15.9 Million
Q2 2018 Aug 14, 2018	BUY	$1.89 - $4.95 $8.32 Million - $21.8 Million	4,400,439 New	4,400,439 $0

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $372M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.